Zapotocka, Ester
Batorova, Angelika
Bilic, Ernest
Boban, Ana
Ettingshausen, Carmen Escuriola
Kotnik, Barbara Faganel
Hrdlickova, Radomira
Laguna, Pawel
Máchal, Jan
Nemes, Laszlo
Zupan, Irena Preloznik
Puras, Gediminas
Zombori, Marianna
Funding for this research was provided by:
Swedish Orphan Biovitrum
Article History
Received: 26 February 2024
Accepted: 5 April 2024
First Online: 16 May 2024
Declarations
:
: Angelika Batorova received honoraria for consultancy and/or speaker fees and/or research funding from Grifols, Novo Nordisk, Octapharma, Pfizer, Sobi, and Takeda. Ana Boban received honoraria as an advisory board member and/or speaker fees from Amgen, AstraZeneca, Bayer, CSL Behring, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, Swixx, and Takeda. Barbara Faganel Kotnik received honoraria for consultancy and/or speaker fees from Bayer, Licentis, Roche, Pfizer, Sobi, and Takeda. Ernest Bilic received honoraria for consultancy and/or speaker fees from Bayer, Octapharma, Novo Nordisk, Pfizer, Roche, and Sobi. Ester Zapotocka received honoraria for consultancy and/or speaker fees from Novo Nordisk, Pfizer, Roche, Sobi, and Takeda. Carmen Escuriola Ettingshausen received honoraria for consultancy and/or speakers fees from Bayer, Biomarin, CSL Behring, Florio HAEMO GmbH, Grifols, Kedrion, LFB, Octapharma, Roche/Chugai, Novo Nordisk, Pfizer, Sobi, and Shire/Takeda. Gediminas Puras is a current employee of Sobi. Radomira Hrdlickova received honoraria for consultancy and/or speaker fees from Bayer, Novo Nordisk, Octapharma, Pfizer, Roche, Sobi, and Takeda. Laszlo Nemes received honoraria for consultancy and/or speaker fees from Novo Nordisk, Sobi, Takeda, Roche, CSL Behring, and Bayer. Marianna Zombori received honoraria for consultancy and/or speaker fees from Bayer, CSL Behring, Octapharma, Novo Nordisk, Pfizer, Takeda, Octapharma, Kedrion, Novartis, Biotest, Sobi, and Roche. Pawel Laguna participated in clinical trials and received remuneration for lectures and consultations from Baxter, Takeda, Bayer Schering Pharma, CSL Behring, Biogen, Grifols, Novo Nordisk, Octapharma, Sobi, and Roche. Irena Preloznik Zupan and Jan Machal report no competing interests.
: This study was conducted in compliance with European General Data Protection Regulation 2016/679, local legislation and Ethics Committee approval (University Hospital Bratislava Ethics Committee) in accordance with the Helsinki Declaration of 1964 and its later amendments. All participants provided informed consent for partaking in the study and any subsequent publication.